In the small first-in-human study, AB-1002 showed an encouraging safety profile and early signs of efficacy, investigators ...

Takeda will pay $1.2 billion upfront, including a $100 million equity investment, for rights to two programs and the option to license a third candidate.

Triple-negative breast cancer patients on Keytruda had significantly improved response rates compared to chemo, despite taking one tenth the standard dose.

NEW YORK – BioNTech said Wednesday that it began an exchange offer to complete its $1.25B all-stock acquisition of mRNA immunotherapy developer CureVac, a deal that was announced in June.

Under the deal, which was first announced in September, Novartis will pay Arrowhead $200 million upfront. Arrowhead is eligible for additional payments of up to $2 billion tied to development, ...

In two Phase I trials, researchers safely administered CAR T cells to high-grade glioma patients and are exploring ways to ...

The company will hold off on making a regulatory decision until it sees results from another trial testing the drug with ...

The registrational trial of AD04 could launch as early as mid-2026, if the company is able to shore up necessary funds or ...

As Novartis moves ahead plans to expand Pluvicto's use based on the PSMAddition trial, experts urge for greater use of ...

In this tough-to-treat cancer type, more patients receiving anzu-cel saw their tumors shrink and had durable responses than what's been seen with other therapies.

The firm will launch a Phase I trial in healthy volunteers in the Netherlands to establish safety and proof-of-target engagement.

NEW YORK – Galapagos on Tuesday said that after a strategic review it has decided to wind down its cell therapy business, which includes several CAR T-cell therapies in development for blood cancers ...